WO2018218970A1

WO2018218970A1 - Medical conductive hydrogel, preparation method therefor and use thereof

Info

Publication number: WO2018218970A1
Application number: PCT/CN2018/072343
Authority: WO
Inventors: 包磊
Original assignee: 深圳市前海未来无限投资管理有限公司
Priority date: 2017-06-02
Filing date: 2018-01-12
Publication date: 2018-12-06
Also published as: CN108210940A

Abstract

Disclosed are a medical conductive hydrogel, a preparation method therefor and the use thereof. The hydrogel comprises 8.00-20.00% of a water-soluble macromolecular material, 0.05-2.00% of -zirconium hydrogen phosphate, 0.20-10.00% of a salt electrolyte and 68-91% of water. In the hydrogel, the -zirconium hydrogen phosphate and the dissolved salt electrolyte are dispersed in the water-soluble macromolecular material. By means of the synergistic effect of the -zirconium hydrogen phosphate and the dissolved salt electrolyte with the water-soluble macromolecular material, the hydrogel has excellent biocompatibility and conductivity, and can be used in the medical field. No hot press moulding is required during preparation, thereby simplifying the preparation process, reducing production costs, and being safety and environmentally friendly.

Description

Medical conductive hydrogel and preparation method and application thereof

Technical field

The invention belongs to the technical field of hydrogels, and in particular relates to a medical conductive hydrogel and a preparation method and application thereof.

Background technique

Conductive hydrogel is a kind of smart hydrogel, which forms electro-active molecules in the internal network structure of highly hydrophilic gel by copolymerization, crosslinking, grafting, doping, etc., which combines gel properties and electrical activity. characteristic. The gel component imparts high hydrophilicity, swellability, good biocompatibility, and high diffusivity of small molecules in a three-dimensional network structure. Electroactive molecules make the composite possess high conductivity, electrochemical redox, electromechanical conversion, and the like. The combination of the two breaks through the bottleneck that many electroactive materials can not be used in bio-matrix, and has important application value in the field of medical devices.

However, there are many varieties of conductive hydrogels in the prior art, usually based on a gel material, and conductive polymers, carbon nanotubes, graphene, graphene oxide, metal nanoparticles, etc. are prepared by blending, doping, etc. . A biocompatible photothermally responsive self-healing conductive hydrogel as disclosed herein, which is an N,N-dimethylacrylamide monomer, an initiator potassium persulfate, and an accelerator N, N, N ', N'-tetramethylethylenediamine is formulated into a monomer solution, and then the graphene hydrogel is immersed in the above monomer solution for solution replacement, allowed to stand, and finally, polymerization is initiated at room temperature. The disclosed conductive hydrogel uses graphene as a three-dimensional network skeleton, and the graphene has high degree of reduction, good chemical stability, high electrical conductivity, high mechanical strength, good photothermal conversion effect, and imparts a hydrogel in the body temperature range and It exhibits good self-healing properties under near-infrared light. However, in the existing conductive hydrogel, the conductive agent is prone to agglomeration and the like, and the dispersion is uneven, thereby causing the hydrogel to be electrically conductive, mechanically unstable, and the biocompatibility is not ideal. Moreover, it is generally not directly usable in the medical field. If it is used in the medical field, it is necessary to additionally add an antibacterial component, and the existing conductive hydrogel has uncontrollable color and high price of the conductive material.

Summary of the invention

The object of the present invention is to overcome the deficiencies of the prior art and to provide a method for preparing a medical conductive hydrogel, which solves the technical problem that the current conductive hydrogel has poor biocompatibility and unstable electrical conductivity.

In order to achieve the above object, in an aspect of the invention, a medical conductive hydrogel is provided. The medical conductive hydrogel comprises the following mass percentage components:

In another aspect of the invention, a method of making a medically conductive hydrogel is provided. The method for preparing the medical conductive hydrogel comprises the following basic steps:

The component and the proportion thereof contained in the medical conductive hydrogel according to the present invention are respectively measured to comprise a water-soluble polymer material, a zirconium hydrogen phosphate and a salt electrolyte raw material, and water;

Dispersing α-zirconium hydrogen phosphate into water to form an α-zirconium hydrogen phosphate dispersion;

Dissolving the water-soluble polymer material in water at 80-120 ° C to prepare a suspension of water-soluble polymer material;

The temperature of the water-soluble polymer material suspension is lowered to below 50 ° C, and the α-zirconium hydrogen phosphate dispersion liquid and a salt electrolyte are added for mixing treatment to form a mixture system;

The mixture system was added to a sizing container for a cyclic freeze-thaw treatment.

In still another aspect of the present invention, there is provided an application of the medical conductive hydrogel of the present invention in the field of electrocardiogram, electroencephalogram, and myoelectric electrodes.

Compared with the prior art, the medical conductive hydrogel of the present invention introduces nano-material α-zirconium hydrogen phosphate into the water-soluble polymer material, and the α-hydrogen phosphate zirconium and the water-soluble polymer material pass hydrogen bonding to achieve physical interaction. Union to enhance the mechanical properties of hydrogels. The easily soluble salt electrolyte is doped to play an ion conductive role in the water-soluble polymer material. The medical conductive hydrogel of the present invention has excellent biocompatibility and electrical conductivity by the synergistic action of the water-soluble polymer material of zirconium hydrogen phosphate and the easily soluble salt electrolyte, and can be applied to the medical field.

The method for preparing a medical conductive hydrogel of the present invention adopts a cyclic freeze-thaw treatment to form a mixed solution of a water-soluble polymer material containing α-zirconium hydrogen phosphate and a salt electrolyte to form a conductive hydrogel which can be used for medical treatment, and The medical conductive hydrogel of the invention has excellent biocompatibility and electrical conductivity and is low in economic cost. In addition, the preparation method of the invention does not require hot press forming, which simplifies the preparation process thereof, reduces the production cost, and is safe and environmentally friendly.

It is because the medical conductive hydrogel of the invention has excellent biocompatibility and electrical conductivity, and has low economic cost, effectively expanding its application in the medical field and improving the biocompatibility of its contact with the human body, and Increased sensitivity to signal collection.

detailed description

In order to make the objects, technical solutions and advantages of the present invention more comprehensible, the present invention will be further described in detail below with reference to the embodiments. It is understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

The quality of the relevant components mentioned in the description of the embodiments of the present invention may not only refer to the proportional relationship of the components, but also the specific content of the mass between the components. Therefore, the proportions of the relevant components in the specification according to the embodiments of the present invention are enlarged or reduced in proportion to the extent disclosed in the specification of the embodiments of the present invention. Specifically, the mass described in the specification of the embodiment of the present invention may be a mass unit well known in the chemical industry such as μg, mg, g, kg, and the like.

Embodiments of the present invention provide a medical conductive hydrogel having excellent biocompatibility and electrical conductivity. The medical conductive hydrogel of the present invention comprises the following mass percentage components:

The water-soluble polymer material contained in the medical conductive hydrogel is a gel matrix. In one embodiment, the water soluble polymeric material is chitosan and chitosan derivatives, hydroxyethyl cellulose, hydroxymethyl cellulose, carbomer, polyvinyl alcohol, polyacrylic acid, gelatin, sodium alginate. One or more of polyethylene glycols. The water-soluble polymer materials are selected as monomers for synthesizing hydrogels, which are non-toxic, safe, inexpensive, have good biocompatibility, and are in contact with the skin, and are ideal raw materials for preparing traditional hydrogels. After the nano material is reinforced and introduced into the conductive ions, the application requirements of the medical conductive hydrogel can be met.

The α-zirconium hydrogen phosphate contained in the medical conductive hydrogel is a regular hexagonal sheet-like structure, and the surface contains a large amount of -OH, and forms a hydrogen bond with a hydroxyl group in the water-soluble polymer material to physically crosslink. Cyclic freezing-thawing plays a role in enhancing hydrogen bonding, so that the prepared nanocomposite hydrogel has excellent mechanical properties and can meet medical requirements. In one embodiment, the α-zirconium hydrogen phosphate has a particle diameter of 100 to 500 nm. The α-zisium hydrogen phosphate having the particle diameter can be uniformly dispersed in the above-mentioned medical conductive hydrogel to improve the mechanical properties and mechanical strength of the medical conductive hydrogel.

The salt-based electrolyte contained in the above-mentioned medical conductive hydrogel can be dispersed in the form of ions in the gel due to its electrolyte property, and the above-mentioned medical treatment is excellent in the antibacterial effect and excellent electrical conductivity imparted to the medical conductive hydrogel. The conductive hydrogel is electrically conductive and particularly stable. In one embodiment, the salt electrolyte is one or more of NaCl, Na2SO4, NaNO3, KCl, K2SO4, KNO3, and AgNO3.

The water contained in the above medical conductive hydrogel may be selected from medical water such as deionized water.

In addition to the above embodiments, the medical conductive hydrogel further contains a pigment. The amount of the pigment to be added may be adjusted according to the application requirements of the above-mentioned medical conductive hydrogel. For example, in one embodiment, the pigment has a content of 0.01 to 0.5 Torr in the medical conductive hydrogel. In a specific embodiment, the pigment is one or more of methylene blue, amaranth, and carmine.

Therefore, the above-mentioned medical conductive hydrogel has a synergistic effect of zirconium a-hydrogen phosphate and a dissolved salt electrolyte and a water-soluble polymer material by dispersing α-zirconium hydrogen phosphate and a soluble salt electrolyte in a water-soluble polymer material. The medical conductive hydrogel of the invention has excellent biocompatibility and electrical conductivity, improves the application value thereof in the medical field, and is economical, safe and environmentally friendly.

Correspondingly, an embodiment of the present invention further provides a preparation method of the medical conductive hydrogel of the embodiment of the present invention. The method for preparing the medical conductive hydrogel comprises the following steps:

S01: according to the composition and proportion of the medical conductive hydrogel according to the above invention, the water-soluble polymer material, α-hydrogen phosphate zirconium and salt electrolyte raw materials and water are respectively measured;

S02: dispersing α-zirconium hydrogen phosphate measured in step S01 into water to form a zirconium a-hydrogen phosphate dispersion;

S03: dispersing the water-soluble polymer material taken in step S01 at 80 to 120 ° C to prepare a water-soluble polymer material suspension;

S04: reducing the temperature of the water-soluble polymer material suspension prepared in step S03 to below 50 ° C, and adding the α-zirconium hydrogen phosphate dispersion prepared in step S02 and the salt electrolyte to perform a mixture treatment to form a mixture system;

S05: The mixture system prepared in the step S04 is added to a sizing container for cyclic freezing treatment-thawing treatment.

Specifically, in the above step S01, the components and contents of the components of the medical conductive hydrogel are as referred to in the above-mentioned medical conductive hydrogel, and the details are not described herein.

In the above step S02, the α-zirconium hydrogen phosphate dispersion can be prepared according to a conventional method. In order to improve the dispersion of α-hydrogen zirconium phosphate and the stability of the dispersion, in one embodiment, the preparation method is α-phosphate. The zirconium hydroxide is dispersed in water and ultrasonically dispersed for 30 to 60 minutes to prepare an ultrasonic dispersion having a mass concentration of not more than 4.00%.

In the above step S03, the water-soluble polymer material is dispersed in water at 80 to 120 ° C. It is understood that the water-soluble polymer material is sufficiently dispersed. In an embodiment, the water-soluble polymer material is dispersed at 80 to 120 ° C by stirring. Into the water; wherein the stirring rate is 800 to 1200 r / min, stirring for 6 to 10 minutes.

In one embodiment, the mass concentration of the water-soluble polymer material suspension prepared at the temperature is controlled to be 16% to 40%. In a further embodiment, after the suspension of the water-soluble polymer material is to be formulated, the suspension is further subjected to a stirring treatment at 100-200 r/min. By controlling the concentration of the water-soluble polymer material suspension and subsequent treatment, the dispersion of the water-soluble polymer material suspension is high, and the dispersion system is stable.

In the above step S04, the salt electrolyte is preferably added in the form of a solution, such as a salt electrolyte solution having a mass percentage of 2.00 to 8.00%. This allows the salt electrolyte to be sufficiently dispersed in the mixture to ensure high electrical conductivity and electrical stability of the final medical conductive hydrogel.

In addition to the above respective embodiments, in the step S04, a dye is mixed with the α-zirconium hydrogen phosphate dispersion and the salt electrolyte to carry out a mixing treatment. The amount of the pigment added is as described above in the medical conductive hydrogel, and can be adjusted according to the application requirements of the medical conductive hydrogel. For example, in one embodiment, the pigment is in the above-mentioned medical conductive hydrogel. It is 0.01-0.5 ‰. In a specific embodiment, the pigment is one or more of methylene blue, amaranth, and carmine.

In the above step S05, the above mixture system forms a gel system during the cyclic freeze-thaw treatment. In one embodiment, the temperature of the freezing treatment in the cyclic freezing treatment-thawing treatment is -18 to -40 ° C, and the freezing time is 4 to 8 hours. In another embodiment, the temperature of the thawing treatment in the circulation freeze-thaw treatment is normal temperature, and the thawing time is 2-4 hours. In a specific embodiment, the freezing treatment and the thawing treatment are repeated for 3-5 times in a cycle. By controlling the conditions of gel formation, based on the components contained therein, the above mixture system is formed into an excellent and stable conductive hydrogel, and imparts biocompatibility to the medical field. Application value.

According to the preparation method of the above medical conductive hydrogel, the medical conductive hydrogel prepared by the invention has excellent biocompatibility and electrical conductivity, and has low economic cost, and the preparation method thereof does not require hot press forming, thereby effectively simplifying the preparation process thereof. , safe and environmentally friendly.

On the other hand, in the medical conductive hydrogel of the embodiment of the invention described above and the preparation method thereof, the medical conductive hydrogel has excellent biocompatibility and electrical conductivity, low economic cost, safety and environmental protection. Therefore, it can be used in the field of electrocardiogram, electroencephalogram, and electromyography electrodes, thereby improving the biocompatibility of its contact with the human body and improving its sensitivity to signal collection.

The medical conductive hydrogel of the present invention and a preparation method thereof will be described in detail below in conjunction with specific preferred embodiments.

Example 1

This embodiment provides a medical conductive hydrogel and a preparation method thereof. The medical conductive hydrogel of this embodiment includes polyvinyl alcohol, α-zirconium hydrogen phosphate, NaCl, and deionized water.

The preparation method of the medical conductive hydrogel of this embodiment is as follows:

Step S11: taking 0.03 g of α-zirconium hydrogen phosphate dispersed into 10.00 mL of deionized water and ultrasonically dispersing for 60 min to prepare an ultrasonic dispersion of α-zirconium hydrogen phosphate;

Step S12: Disperse 3.00 g of polyvinyl alcohol 1799 into 30.00 mL of deionized water, stir at 90 ° C for 10 min, and stir at a rate of 1000 r / min to obtain a suspension of polyvinyl alcohol 1799, after which the heating was stopped, and the resulting suspension was Stirring at 200 r/min;

Step S13: After the temperature of the suspension obtained in the step S12 is lowered to below 50 ° C, the ultrasonic dispersion of α-zirconium hydrogen phosphate in step S11 and 2.00 g of NaCl are added to the suspension obtained in the step S12, and added dropwise. 1~2 drops of methylene blue dilution to adjust the color, stir until the system is evenly mixed;

Step S14: adding the mixture obtained in step S13 to the mold and sealing;

Step S15: the mold containing the mixed liquid in step S14 is placed in a -20 ° C freezer for 6 h, then taken out, and placed at room temperature for 3 h to thaw;

Step S16: Step S15 is repeated three times, and the mold is taken out to obtain a medical conductive hydrogel.

Example 2

Step S21: taking 0.03 g of α-zirconium hydrogen phosphate dispersed into 10.00 mL of deionized water and ultrasonically dispersing for 60 min to prepare an ultrasonic dispersion of α-zirconium hydrogen phosphate;

Step S22: 6.00 g of polyvinyl alcohol 1799 was dispersed in 30.00 mL of deionized water, stirred at 90 ° C for 10 min, and the stirring rate was 1000 r / min to obtain a suspension of polyvinyl alcohol 1799, after which the heating was stopped, and the resulting suspension was Stirring at 200 r/min;

Step S23: after the temperature of the suspension obtained in the step S22 is lowered to 50 ° C or lower, the ultrasonic dispersion of α-zirconium hydrogen phosphate in step S21 and 4.00 g of NaCl are added to the suspension obtained in the step S22, and added dropwise. 1~2 drops of methylene blue dilution to adjust the color, stir until the system is evenly mixed;

Step S24: adding the mixture obtained in step S23 to the mold and sealing;

Step S25: the mold containing the mixed liquid in step S24 is placed in a -20 ° C freezer for 6 h, then taken out, and placed at room temperature for 3 h to thaw;

Step S26: Step S25 is repeated three times, and the mold is taken out to obtain a medical conductive hydrogel.

Example 3

This embodiment provides a medical conductive hydrogel and a preparation method thereof. The medical conductive hydrogel of this embodiment includes chitosan, α-zirconium hydrogen phosphate, NaCl, and deionized water.

Step S31: taking 0.03 g of α-zirconium hydrogen phosphate dispersed into 10.00 mL of deionized water and ultrasonically dispersing for 60 min to prepare an ultrasonic dispersion of α-zirconium hydrogen phosphate;

Step S32: Disperse 3.00 g of chitosan into 30.00 mL of deionized water, add acetic acid dropwise, adjust the pH to about 5, stir at 120 ° C for 10 min, and stir at a rate of 1000 r / min to obtain a suspension of chitosan. Heating was stopped and the resulting suspension was stirred at 200 r/min;

Step S33: After the temperature of the suspension obtained in step S32 is lowered to below 50 ° C, the ultrasonic dispersion of α-zirconium hydrogen phosphate and 2.00 g of NaCl in step S31 are added to the suspension obtained in step S32, and 1 is added dropwise. ～2 methylene blue dilution to adjust the color, stir until the system is evenly mixed;

Step S34: adding the mixture obtained in step S33 to the mold and sealing;

Step S35: the mold containing the mixed liquid in step S34 is placed in a -20 ° C freezer for 6 h, then taken out, and placed at room temperature for 3 h to thaw;

Step S36: Step S35 is repeated three times, and the mold is taken out to obtain a medical conductive hydrogel.

Example 4

This embodiment provides a medical conductive hydrogel and a preparation method thereof. The medical conductive water gel of this embodiment includes chitosan, α-zirconium hydrogen phosphate, NaCl, and deionized water.

Step S41: taking 0.03 g of α-zirconium hydrogen phosphate dispersed into 10.00 mL of deionized water and ultrasonically dispersing for 60 min to prepare an ultrasonic dispersion of α-zirconium hydrogen phosphate;

Step S42: Disperse 6.00 g of chitosan into 30.00 mL of deionized water, add acetic acid dropwise, adjust the pH to about 5, stir at 120 ° C for 10 min, and stir at a rate of 1000 r/min to obtain a suspension of chitosan. Heating was stopped and the resulting suspension was stirred at 200 r/min;

Step S43: after the temperature of the suspension obtained in step S42 is lowered to below 50 ° C, the ultrasonic dispersion of α-zirconium hydrogen phosphate and 4.00 g of NaCl in step S41 are added to the suspension obtained in step S42, and added dropwise. 1~2 methylene blue dilution liquid to adjust the color, stir until the system is evenly mixed;

Step S44: adding the mixture obtained in step S43 to the mold and sealing;

Step S45: the mold containing the mixed liquid in step S44 is placed in a -20 ° C freezer for 6 h, then taken out, and placed at room temperature for 3 h to thaw;

Step S46: Step S45 is repeated three times, and the mold is taken out to obtain a medical conductive hydrogel.

Example 5

This embodiment provides a medical conductive hydrogel and a preparation method thereof. The medical conductive hydrogel of this embodiment includes polyvinyl alcohol 1799, polyethylene glycol 6000, α-zirconium hydrogen phosphate, NaCl, and deionized water.

Step S51: taking 0.03 g of α-zirconium hydrogen phosphate dispersed into 10.00 mL of deionized water and ultrasonically dispersing for 60 min to prepare an ultrasonic dispersion of α-zirconium hydrogen phosphate;

Step S52: Disperse 2.00 g of polyvinyl alcohol 1799 and 1.00 g of polyethylene glycol 6000 into 30.00 mL of deionized water, stir at 90 ° C for 10 min, and stir at a rate of 1000 r / min to obtain polyvinyl alcohol 1799 and polyethylene glycol. a mixed suspension of 6000, after which the heating was stopped, and the resulting suspension was stirred at 200 r/min;

Step S53: after the temperature of the suspension obtained in the step S52 is lowered to 50 ° C or lower, the ultrasonic dispersion of α-zirconium hydrogen phosphate in step S51 and 2.00 g of NaCl are added to the suspension obtained in the step S52, and added dropwise. 1~2 methylene blue dilution liquid to adjust the color, stir until the system is evenly mixed;

Step S54: adding the mixture obtained in step S53 to the mold and sealing;

Step S55: The mold containing the mixed liquid in step S54 is placed in a -20 ° C freezer for 6 h, then taken out, and placed at room temperature for 3 h to thaw;

Step S56: Step S55 is repeated three times, and the mold is taken out to obtain a medical conductive hydrogel.

Example 6

This embodiment provides a medical conductive hydrogel and a preparation method thereof. The medical conductive hydrogel of this embodiment includes Carbomer 940, α-zirconium hydrogen phosphate, NaCl, and deionized water.

Step S61: taking 0.03 g of α-zirconium hydrogen phosphate dispersed into 10.00 mL of deionized water and ultrasonically dispersing for 60 min to prepare an ultrasonic dispersion of α-zirconium hydrogen phosphate;

Step S62: Disperse 3.00 g of carbomer 940 into 30.00 mL of deionized water, stir at 90 ° C for 10 min, and stir at a rate of 1000 r / min to obtain a suspension of carbomer 940, and then stop heating, and the resulting suspension is Stirring at 200 r/min;

Step S63: after the temperature of the suspension obtained in the step S62 is lowered to 50 ° C or lower, the ultrasonic dispersion of α-zirconium hydrogen phosphate in step S61 and 2.00 g of NaCl are added to the suspension obtained in the step S62, and added dropwise. 1~2 methylene blue dilution liquid to adjust the color, stir until the system is evenly mixed;

Step S64: adding the mixture obtained in step S63 to the mold and sealing;

Step S65: the mold containing the mixed liquid in step S64 is placed in a -20 ° C freezer for 6 h, then taken out, and placed at room temperature for 3 h to thaw;

Step S66: Step S65 is repeated three times, and the mold is taken out to obtain a medical conductive hydrogel.

Example 7

This embodiment provides a medical conductive hydrogel and a preparation method thereof. The medical conductive hydrogel of this example comprises polyvinyl alcohol 1799, carbomer 940, NaCl, and deionized water.

Step S71: taking 0.03 g of α-zirconium hydrogen phosphate dispersed into 10.00 mL of deionized water and ultrasonically dispersing for 60 min to prepare an ultrasonic dispersion of α-zirconium hydrogen phosphate;

Step S72: 2.00 g of polyvinyl alcohol 1799 and 1.00 g of carbomer 940 were dispersed into 30.00 mL of deionized water, stirred at 90 ° C for 10 min, and the stirring rate was 1000 r / min to obtain polyvinyl alcohol 1799 and carbomer 940. Suspension, then heating was stopped, and the resulting suspension was stirred at 200 r/min;

Step S73: after the temperature of the suspension obtained in the step S72 is lowered to 50 ° C or lower, the ultrasonic dispersion of α-zirconium hydrogen phosphate in step S71 and 2.00 g of NaCl are added to the suspension obtained in the step S72, and added dropwise. 1~2 methylene blue dilution liquid to adjust the color, stir until the system is evenly mixed;

Step S74: adding the mixture obtained in step S73 to the mold and sealing;

Step S75: the mold containing the mixed liquid in step S74 is placed in a -20 ° C freezer for 6 h, then taken out, and placed at room temperature for 3 h to thaw;

Step S76: Step S75 is repeated three times, and the mold is taken out to obtain a medical conductive hydrogel.

Example 8

This embodiment provides a medical conductive hydrogel and a preparation method thereof. The medical conductive hydrogel of this example comprises polyvinyl alcohol 1799, gelatin, NaCl, and deionized water.

Step S81: taking 0.03 g of α-zirconium hydrogen phosphate dispersed into 10.00 mL of deionized water and ultrasonically dispersing for 60 min to prepare an ultrasonic dispersion of α-zirconium hydrogen phosphate;

Step S82: Disperse 2.00 g of polyvinyl alcohol 1799 and 1.00 g of gelatin into 30.00 mL of deionized water, stir at 90 ° C for 10 min, and stir at a rate of 1000 r / min to obtain a suspension of polyvinyl alcohol 1799 and gelatin, and then stop heating. The resulting suspension was stirred at 200 r/min;

Step S83: After the temperature of the suspension obtained in the step S82 is lowered to 50 ° C or lower, the ultrasonic dispersion of α-zirconium hydrogen phosphate in step S81 and 2.00 g of NaCl are added to the suspension obtained in the step S82, and added dropwise. 1~2 methylene blue dilution liquid to adjust the color, stir until the system is evenly mixed;

Step S84: adding the mixture obtained in step S83 to the mold and sealing;

Step S85: the mold containing the mixed liquid in step S84 is placed in a -20 ° C freezer for 6 h, then taken out, and placed at room temperature for 3 h to thaw;

Step S86: Step S85 is repeated three times, and the mold is taken out to obtain a medical conductive hydrogel.

Related performance tests:

The medical conductive hydrogels prepared in the above Examples 1-8 were subjected to the relevant performance tests in Table 1 below, and the test results are shown in Table 1. Among them, conductivity, biocompatibility, and ECG signal acquisition applications are in accordance with commonly used test methods in the industry.

Table 1

It can be seen from Table 1 that the medical conductive hydrogel of the embodiment of the invention has excellent biocompatibility and electrical conductivity, and can ensure the sensitivity and stability of ECG signal acquisition.

The above is only the preferred embodiment of the present invention, and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection of the present invention. Within the scope.

Claims

A medical conductive hydrogel comprising the following mass percentage components:
The medical conductive hydrogel according to claim 1, wherein the α-zirconium hydrogen phosphate has a particle diameter of from 100 nm to 500 nm.
The medical conductive hydrogel according to claim 1, wherein the water-soluble polymer material is chitosan and chitosan derivatives, hydroxyethyl cellulose, hydroxymethyl cellulose, and carbomer. , one or more of polyvinyl alcohol, polyacrylic acid, gelatin, sodium alginate, polyethylene glycol; and/or

The salt electrolyte is one or more of NaCl, Na2SO4, NaNO3, KCl, K2SO4, KNO3, and AgNO3.
The medical conductive hydrogel according to any one of claims 1 to 3, wherein the medical conductive hydrogel further comprises a pigment.
The medical conductive hydrogel according to claim 4, wherein the pigment is contained in an amount of from 0.01 to 0.5 Å; and/or

The pigment is one or more of methylene blue, amaranth, and carmine.
A method for preparing a medical conductive hydrogel comprises the following steps:

The composition and ratio of the medical conductive hydrogel according to any one of claims 1 to 5, respectively, comprising a water-soluble polymer material, a-hydrogen zirconium hydrogen phosphate and a salt electrolyte material, and water;

Dispersing α-zirconium hydrogen phosphate into water to form an α-zirconium hydrogen phosphate dispersion;

Dissolving the water-soluble polymer material in water at 80-120 ° C to prepare a suspension of water-soluble polymer material;

The temperature of the water-soluble polymer material suspension is lowered to below 50 ° C, and the α-hydrogen zirconium phosphate dispersion liquid and a salt electrolyte are added for mixing treatment to form a mixture system;

The mixture system is added to a qualitative container for cyclic freeze-thaw treatment.
The preparation method according to claim 6, wherein the freezing treatment temperature in the cyclic freezing treatment-thawing treatment is -18 to -40 ° C, and the freezing time is 4 to 8 hours; and/or

The thawing treatment temperature in the circulation freezing treatment-thawing treatment is normal temperature, and the thawing time is 2-4 hours.
The preparation method according to claim 7, wherein the number of cycles of the circulation freezing treatment-thawing treatment is 3-5 times.
The preparation method according to any one of claims 6 to 8, characterized in that the mass concentration of the α-zirconium hydrogen phosphate dispersion is not more than 4%; and/or

The water-soluble polymer material suspension has a mass concentration of 16% to 40%.
The medical conductive hydrogel according to any one of claims 1 to 5 or the medical conductive hydrogel prepared by the preparation method according to any one of claims 6 to 9 in the field of electrocardiogram, electroencephalogram, and electromyography electrode.